- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.09. | Merck KGaA and Siemens extend digital transformation partnership in life sciences | ||
| 22.09. | Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn | ||
| 22.09. | MSD wins SC Keytruda approval, but analysts sceptical on impact | ||
| 22.09. | Stealth Bio's Forzinity finally approved as first Barth syndrome therapy | ||
| 22.09. | Ionis and Sobi's Tryngolza gains approval in EU for FCS treatment | ||
| 22.09. | Astellas' Izervay gains conditional approval in Japan for GA treatment | ||
| 19.09. | Bluebird bio flies to pastures new with Genetix rebranding | ||
| 19.09. | FUJIFILM Biotechnologies and argenx expand global partnership | ||
| 19.09. | VectorY enters agreement with Shape Therapeutics for AAV capsid | ||
| 18.09. | Roche signs agreement to acquire 89bio in $2.4bn deal | ||
| 18.09. | Biogen's Zurzuvae approved as first postpartum depression drug in Europe | ||
| 18.09. | Big pharma companies hit with FDA warning letters in drug ad clampdown | ||
| 17.09. | GSK plans $30bn investment for R&D in US | ||
| 17.09. | Eli Lilly picks Virginia for $5bn drug manufacturing plant | ||
| 17.09. | Reunion Neuroscience expands Series A to $133m after positive trial milestones | ||
| 17.09. | VarmX and CSL form alliance for blood coagulation treatment development | ||
| 16.09. | Novo Nordisk secures EMA approval for Rybelsus label update | ||
| 16.09. | Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors | ||
| 16.09. | aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail | ||
| 15.09. | Novartis returns to Monte Rosa for second time in a year with $5.7bn deal | ||
| 15.09. | Amneal secures FDA approval for sodium oxybate solution | ||
| 15.09. | AstraZeneca halts £200m research investment in Cambridge | ||
| 15.09. | LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut | ||
| 15.09. | FDA chief blames decades of regulatory failure for misleading pharma ads | ||
| 12.09. | AbbVie extends Rinvoq exclusivity by four years after generics settlements |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .